This is a working overview of Pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-16 and is reviewed periodically as new material appears.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
== New roles == Recent findings suggest that StAR may also traffic cholesterol to a second mitochondrial enzyme, sterol 27-hydroxylase. This enzyme converts cholesterol to 27-hydroxycholesterol. In this way it may be important for the first step in one of the two pathways for the production of bile acids by the liver (the alternative pathway). Evidence also shows that the presence of StAR in a type of immune cell, the macrophage, where it can stimulate the production of 27-hydroxycholesterol. In this case, 27-hydroxycholesterol may by itself be helpful against the production of inflammatory factors associated with cardiovascular disease. No study has yet found a link between the loss of StAR and problems in bile acid production or increased risk for cardiovascular disease. Recently StAR was found to be expressed in cardiac fibroblasts in response to ischemic injury due to myocardial infarction. In these cells it has no apparent de novo steroidogenic activity, as evidenced by the lack of the key steroidogenic enzymes cytochrome P450 side chain cleavage (CYP11A1) and 3 beta hydroxysteroid dehydrogenase (3βHSD). StAR was found to have an anti-apoptotic effect on the fibroblasts, which may allow them to survive the initial stress of the infarct, differentiate and function in tissue repair at the infarction site.
=== Person-centred approach === Person-centred clinical management is widely recognised as an effective and sustainable model for chronic disease care. Kalra has extensively applied person-centred principles to insulin initiation and intensification. He has also examined barriers to insulin use, especially in low- and middle-income countries, and suggested frameworks ("bridges") to address these challenges. Kalra has been lead author for several multinational panels and evidence-based recommendations on individualising time-in-range goals, and on administration techniques, including work published in Mayo Clinic Proceedings.
2006: Chilean biochemist Cecilia Hidalgo Tapia became the first woman to receive the Chilean National Prize for Natural Sciences. 2006: Chinese-American biochemist Yizhi Jane Tao led a team of researchers to become the first to map the atomic structure of Influenza A, contributing to antiviral research. 2006: Parasitologist Susan Lim became the first Malaysian scientist elected to the International Commission on Zoological Nomenclature. 2006: Merieme Chadid became the first Moroccan person and the first female astronomer to travel to Antarctica, leading an international team of scientists in the installation of a major observatory in the South Pole. 2006: American computer scientist Frances E. Allen won the Turing Award for "pioneering contributions to the theory and practice of optimizing compiler techniques that laid the foundation for modern optimizing compilers and automatic parallel execution". She was the first woman to win the award. 2006: Israeli crystallographer Ada E. Yonath became the first woman awarded the Wolf Prize in Chemistry for "ingenious structural discoveries of the ribosomal machinery of peptide-bond formation and the light-driven primary processes in photosynthesis." 2006: Canadian-American computer scientist Maria Klawe became the president of Harvey Mudd College. 2007: Using satellite imagery, Egyptian geomorphologist Eman Ghoneim discovered traces of an 11,000-year-old mega lake in the Sahara Desert. The discovery shed light on the origins of the largest modern groundwater reservoir in the world.
Sources: en.wikipedia.org
=== Astrobiology === To understand the prospects for life to exist elsewhere in the universe, astrobiologists are interested in measuring the chemical composition of extraplanetary bodies. Because of their small size and wide-ranging functionality, microfluidic devices are suited for these remote sample analyses. From an extraterrestrial sample, the organic content can be assessed using microchip capillary electrophoresis and selective fluorescent dyes. These devices are capable of detecting amino acids, peptides, fatty acids, and simple aldehydes, ketones, and thiols. These analyses coupled together could allow detection of the key components of life, and inform the search for functioning extraterrestrial life.
== External links == Termination+Release+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
==== Hypothetical: With Great Yarmouth First ==== A poll was commissioned for the constituency of Great Yarmouth for a new (although unregistered at the time) party "Great Yarmouth First" led by Rupert Lowe, prior to the formation of Restore Britain. The sample size of this poll was significantly smaller than standard polling leading to a wider margin of error. Great Yarmouth First was registered with the Electoral Commission as a political party on 4 March 2026.
Methenamine, also known as 1,3,5,7-tetraazaadamantane, is a simple cyclic hydrocarbon with a cage-like structure and is similar in structure to adamantane (tricyclo[3.3.1.13,7]decane). It is specifically the analogue of adamantane in which the carbon atoms at the 1, 3, 4, and 7 positions have been replaced with nitrogen atoms. The drug is a white or colorless and odorless crystalline compound with a sweet, sour, and/or metallic taste. It is a hydrophilic compound with a predicted log P (XLogP3) of 0.3. Methenamine is usually provided medically as the hippuric acid or mandelic acid salt. Methenamine is the cation and hippuric acid or mandelic acid is the anion.
Sources: en.wikipedia.org
The type of a mass spectrometer most widely used with MALDI is the time-of-flight mass spectrometer (TOF), mainly due to its large mass range. The TOF measurement procedure is also ideally suited to the MALDI ionization process since the pulsed laser takes individual 'shots' rather than working in continuous operation. MALDI-TOF instruments are often equipped with a reflectron (an "ion mirror") that reflects ions using an electric field. This increases the ion flight path, thereby increasing time of flight between ions of different m/z and increasing resolution. Modern commercial reflectron TOF instruments reach a resolving power m/Δm of 50,000 FWHM (full-width half-maximum, Δm defined as the peak width at 50% of peak height) or more. MALDI has been coupled with IMS-TOF MS to identify phosphorylated and non-phosphorylated peptides. MALDI-FT-ICR MS has been demonstrated to be a useful technique where high resolution MALDI-MS measurements are desired.
During the 2023 legislative session, Moore introduced the Family Prosperity Act, which allocates $171 million toward making permanent the earned income tax credit passed by lawmakers in 2021, and the Keep Our Heroes Home Act, which provides $33 million for expanding tax exemptions for military retirement income; legislators later scaled down the Keep Our Heroes Home Act to only raise the state's income exemption limit to $20,000 for older veterans and $12,500 for younger ones. Moore signed both bills into law in April and May 2023, as well as another bill to allow workers to deduct union dues from their income taxes. In August 2023, following a report from the Maryland Department of Legislative Services predicting that the state's budget deficits would increase to $1.8 billion annually by 2028, Moore cautioned that the state would enter a "season of discipline". He also pledged to hire a chief performance officer, later naming Asma Mirza, the deputy for implementation management for the White House Infrastructure Implementation Team, to the position. During the 2024 legislative session, Moore opposed proposals to raise income taxes to correct the state's incoming budgetary woes, instead proposing a budget that would significantly cut funding for transportation and higher education projects; legislators were able to avert many of the proposed transportation cuts by raising taxes on tobacco products, raising tolls, and increasing vehicle registration fees.
UPMC Kildare Hospital is a 39-bed private hospital located in County Kildare, Ireland (founded in 1985 as Clane General Hospital). UPMC acquired the hospital in November 2019 in partnership with the Institute of Eye Surgery.
=== Long-Term Potentiation === Long-Term Potentiation (LTP) is the increase in sensitivity of homosynapses that augment the synapse's strength and signal transduction. In the context of OIH, LTP has been shown to contribute to hyperalgesia by hypersensitizing areas of nociceptive processing, particularly at synapses between C fibers and the spinal cord dorsal horn. Studies that attempted to link LTP and hyperalgesia have found that drugs able to block LTP (ketamine and minocycline) also decrease hyperalgesia. In addition, LTP and OIH both utilize NMDA receptors and their activity can be reduced by NMDA receptor antagonists (i.e. ketamine).
First cell cultivation was only allowed in a hospital setting and second academic scientists employed by state-owned universities were not allowed outside employment until 1998. Moreover, the Japanese authorities took longer to approve new drugs and treatments than there US and European counterparts. For these reasons in the early days of the Japanese market, the focus was mainly on getting products that were already approved elsewhere in Japan and selling them. Contrary to the US market the early actors in Japan were mainly big firms or sub-companies of such big firms, such as J-TEC, Menicon and Terumo, and not small startups. After regulatory changes in 2014, which allowed cell cultivation outside of a hospital setting, the speed of research in Japan increased and Japanese companies also started to develop their own products.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.